What does coopervision — research and development expense mean?

Captures the investment in innovation, clinical trials, and the development of new contact lens technologies and specialty lens portfolios. This is a critical driver for long-term competitive advantage in the eyecare industry.

The Cooper Companies, Inc. (COO) CooperVision — Research and development expense

Screener

Other segment segments

CooperSurgical

$20.4M+2.5%

Similar metrics at other companies

FTISubsea — Research and development expense

$16.7M-8.7%

ENOVReconstructive — Research and development expense

$23.98M+14.0%

BDXInterventional — Research and development expense

$72M+14.3%

BDXMedical — Research and development expense

$130.75M+17.0%

GEVOGevoND — Research and development expense

$0—

DBVTExpenses by function — Research and development expense

$9.4M+64.9%

Other financials

Income statement

See full

Revenue$1.1B+7.9%

Gross profit$735.4M+8.3%

Operating income-$31.0M-117%

Net income-$77.9M-189%

EPS (diluted)-$0.40-191%

Balance sheet

See full

Cash & equivalents$139.0M+19.6%

Total debt$3.1B+15.6%

Total equity$8.2B-0.6%

Total assets$12.5B+0.6%

Cash flow

See full

Operating cash flow$182.8M+90.0%

CapEx$86.4M+10.6%

Free cash flow$96.4M+433%

Valuation

See full

Market cap$14.6B+7.4%

Enterprise value$17.52B+9.5%

P/E61.9×+28.6×

P/S3.5×+0.1×

Profitability

See full

Gross margin65.5%-1.6pp

Operating margin11.8%-7.2pp

Net margin5.6%-4.8pp

FCF margin13.5%+4.3pp

Returns & leverage

See full

Return on equity2.9%-2.3pp

Debt / equity0.4×+0.1×

Current ratio1.3×-0.8×

Where this comes from

Reported directly by The Cooper Companies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: The Cooper Companies, Inc.’s 10-Q, filed June 5, 2026.

Filed: Jun 5, 2026, 4:47 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-041305

(In millions) / Three Months Ended April 30, 2026	Cooper Vision	Cooper Surgical	Corporate (1)	Consolidated
Net sales	$723.5	$358.0	—	$1,081.5
Cost of sales	229.4	116.7	—	346.1
Selling, general and administrative expense	252.2	402.4	21.6	676.2
Research and development expense	22.1	20.4	—	42.5
Amortization expense	4.2	43.5	—	47.7
Operating income (loss)	$215.6	$(225.0)	$(21.6)	$(31.0)
Interest expense				20.9
Other (income) expense, net				(3.5)

Item 1. Unaudited Financial Statements

FAQ

What is The Cooper Companies, Inc.'s coopervision — research and development expense?: The Cooper Companies, Inc. (COO) reported coopervision — research and development expense of $22.1M in Q1 2026.
How has The Cooper Companies, Inc.'s coopervision — research and development expense changed year-over-year?: The Cooper Companies, Inc.'s coopervision — research and development expense decreased by 13.7% year-over-year, from $25.6M to $22.1M.
What does coopervision — research and development expense mean?: Captures the investment in innovation, clinical trials, and the development of new contact lens technologies and specialty lens portfolios. This is a critical driver for long-term competitive advantage in the eyecare industry.